Fertility
Dr Raoul Scherwitzl of Natural Cycles joins femble as new angel investor

Just twelve weeks after its strategic realignment, the Innsbruck-based startup femble has achieved another significant milestone: Dr. Raoul Scherwitzl, Co-Founder and Co-CEO of the successful Femtech company Natural Cycles, has joined as a new angel investor.
Originally launched as an app-based health platform for menstrual health issues with an engaged community of over 40,000 women, femble has recently adjusted its business model.
The company now focuses on strengthening the doctor-patient relationship through a digital platform. This strategic shift was driven by extensive market feedback and the needs of medical professionals.
Dr Raoul Scherwitzl brings valuable expertise and a strong network to the partnership, drawing from his experience with Natural Cycles.
His investment underscores confidence in femble’s new direction and the company’s potential to significantly improve information exchange and relationships between doctors and patients.
Raoul Scherwitzl said: “The problem statement convinced me—through my experience in digital health solutions, I know this is a real pain point.
“femble addresses a fundamental need and has the potential to sustainably enhance the interaction between doctors and patients.”
femble Co-Founder Daniel Steiner added: “Raoul’s support is a major milestone for femble. His expertise in the Femtech sector and his commitment to innovative health solutions will help us drive our vision forward.”
Since its founding in 2021, Daniel Steiner and Lina Graf have continuously worked to make medical knowledge more accessible.
With the development of a specialized software solution for doctors and plans for international expansion—including a move into New York—femble is setting new standards in the digital health industry.
femble Co-Founder, Lina Graf, added: “We are thrilled about Raoul’s investment. It validates our approach and motivates us to continue fundamentally strengthening the doctor-patient relationship with femble.”
Wellness
Gum disease may impair female fertility and egg quality – study
Fertility
AI could transform ovarian care through personalisation, study finds

AI could transform ovarian care by personalising cancer and fertility treatment, but more clinical validation is needed before routine use.
A systematic review and meta-analysis found AI models showed high diagnostic accuracy for ovarian cancer when combining data such as ultrasound scans and blood test results.
Across 81 studies, AI models correctly identified ovarian cancer in around nine out of 10 cases, with pooled rates of 89 to 94 per cent.
They were also highly accurate at ruling out ovarian cancer when it was not present, with specificity of 85 to 91 per cent.
The analysis also found that explainable AI tools could predict complete surgical cytoreduction in advanced ovarian cancer.
Complete surgical cytoreduction means removing all visible cancer during surgery, which can be an important goal in treatment planning.
The tools achieved a pooled AUC of 0.87. AUC is a measure of how well a model distinguishes between different outcomes, with higher scores showing stronger performance.
In reproductive medicine, AI algorithms helped physicians optimise ovarian stimulation protocols and predict follicular growth during IVF.
Ovarian stimulation is the use of hormones to encourage the ovaries to produce eggs, while follicles are the small sacs in the ovaries where eggs develop.
The review found AI could reliably model ovarian response in IVF with a pooled AUC of 0.81.
However, researchers said challenges remain in translating promising research findings into routine clinical practice.
They identified substantial variation across studies, driven by retrospective study designs, variable AI systems and a lack of standardised validation.
Only 22 per cent of analysed studies reported prospective, multicentre external validation, where models are tested forward in time across multiple healthcare settings.
The authors called for rigorous validation to help close the gap between research and routine clinical practice, alongside standardised methodological and reporting frameworks, smooth integration with clinical workflow and robust governance to support responsible and ethical AI use.
They concluded: “Artificial intelligence is a transformative force in the management of ovarian conditions.
“In gynaecologic oncology, AI enhances every phase of care, from early detection and accurate diagnosis to prognostic stratification and surgical planning.”
In reproductive medicine, AI personalises ovarian stimulation and refines the diagnosis of heterogenous endocrine disorders such as PCOS.
PCOS, or polycystic ovary syndrome, is a hormonal condition that can affect periods, skin, weight and fertility.
Fertility
Housing, work and fertility stop Britons having the families they want – research
Opinion4 weeks agoWhat Maternal Mental Health Month reveals about where postpartum support actually breaks down
News3 weeks agoNIH Grant terminations disproportionately impact minority scientists, research finds
Menopause5 days agoPerimenopause misinformation ‘putting women at risk’
Adolescent health3 weeks agoWUKA brings Period-Positive Pool Party to London Aquatics Centre to keep girls swimming through puberty
Insight3 weeks agoPCOS renamed after decade-long campaign to end ‘cyst’ misconception
Events4 weeks agoWHIS 2026 unveils agenda and first speakers for the leading women’s health summit
Menopause3 weeks agoCBT shows promise for menopause insomnia and hot flashes
Insight4 weeks agoOnline abuse and deepfakes ‘pushing women out of public life’








